Source: Journal American College of Cardiology. Conference titles: Annual Scientific Session American College of Cardiology. Unidade: FM
Subjects: CARDIOPATIAS, ANGIOPLASTIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
THEROUX, Pierre et al. Markers of inflammation predict mortality and are reduced by pexelizumab in patients with acute myocardial infarction: insights from the complement inhibition in myocardial infartion treated with angiooplasty (COMMA) trial. Journal American College of Cardiology. New York: Faculdade de Medicina, Universidade de São Paulo. . Acesso em: 05 nov. 2024. , 2004APA
Theroux, P., Armstrong, P. W., Gonzales, L. M., Mahaffey, K. W., Hochman, J. S., Rollins, S., et al. (2004). Markers of inflammation predict mortality and are reduced by pexelizumab in patients with acute myocardial infarction: insights from the complement inhibition in myocardial infartion treated with angiooplasty (COMMA) trial. Journal American College of Cardiology. New York: Faculdade de Medicina, Universidade de São Paulo.NLM
Theroux P, Armstrong PW, Gonzales LM, Mahaffey KW, Hochman JS, Rollins S, Malloy KJ, Parish T, Nicolau JC, Lavoie J, Granger CB. Markers of inflammation predict mortality and are reduced by pexelizumab in patients with acute myocardial infarction: insights from the complement inhibition in myocardial infartion treated with angiooplasty (COMMA) trial. Journal American College of Cardiology. 2004 ;43 287A.[citado 2024 nov. 05 ]Vancouver
Theroux P, Armstrong PW, Gonzales LM, Mahaffey KW, Hochman JS, Rollins S, Malloy KJ, Parish T, Nicolau JC, Lavoie J, Granger CB. Markers of inflammation predict mortality and are reduced by pexelizumab in patients with acute myocardial infarction: insights from the complement inhibition in myocardial infartion treated with angiooplasty (COMMA) trial. Journal American College of Cardiology. 2004 ;43 287A.[citado 2024 nov. 05 ]
